Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 582

1.

In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity.

Wise MC, Xu Z, Tello-Ruiz E, Beck C, Trautz A, Patel A, Elliott ST, Chokkalingam N, Kim S, Kerkau MG, Muthumani K, Jiang J, Fisher P, Ramos SJ, Smith TR, Mendoza J, Broderick KE, Montefiori DC, Ferrari G, Kulp DW, Humeau L, Weiner DB.

J Clin Invest. 2019 Nov 7. pii: 132779. doi: 10.1172/JCI132779. [Epub ahead of print]

2.

Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01.

Pinto D, Fenwick C, Caillat C, Silacci C, Guseva S, Dehez F, Chipot C, Barbieri S, Minola A, Jarrossay D, Tomaras GD, Shen X, Riva A, Tarkowski M, Schwartz O, Bruel T, Dufloo J, Seaman MS, Montefiori DC, Lanzavecchia A, Corti D, Pantaleo G, Weissenhorn W.

Cell Host Microbe. 2019 Oct 22. pii: S1931-3128(19)30483-4. doi: 10.1016/j.chom.2019.09.016. [Epub ahead of print]

3.

Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC".

Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL.

J Virol. 2019 Oct 15;93(21). pii: e00968-19. doi: 10.1128/JVI.00968-19. Print 2019 Nov 1. No abstract available.

4.

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.

Pantaleo G, Janes H, Karuna S, Grant S, Ouedraogo GL, Allen M, Tomaras GD, Frahm N, Montefiori DC, Ferrari G, Ding S, Lee C, Robb ML, Esteban M, Wagner R, Bart PA, Rettby N, McElrath MJ, Gilbert PB, Kublin JG, Corey L; NIAID HIV Vaccine Trials Network.

Lancet HIV. 2019 Nov;6(11):e737-e749. doi: 10.1016/S2352-3018(19)30262-0. Epub 2019 Oct 7.

5.

Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields.

Gorman J, Mason RD, Nettey L, Cavett N, Chuang GY, Peng D, Tsybovsky Y, Verardi R, Nguyen R, Ambrozak D, Biris K, LaBranche CC, Ramesh A, Schramm CA, Zhou J, Bailer RT, Kepler TB, Montefiori DC, Shapiro L, Douek DC, Mascola JR, Roederer M, Kwong PD.

Immunity. 2019 Oct 15;51(4):724-734.e4. doi: 10.1016/j.immuni.2019.09.007. Epub 2019 Oct 2.

PMID:
31586542
6.

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial.

Rouphael NG, Morgan C, Li SS, Jensen R, Sanchez B, Karuna S, Swann E, Sobieszczyk ME, Frank I, Wilson GJ, Tieu HV, Maenza J, Norwood A, Kobie J, Sinangil F, Pantaleo G, Ding S, McElrath MJ, De Rosa SC, Montefiori DC, Ferrari G, Tomaras GD, Keefer MC; HVTN 105 Protocol Team and the NIAID HIV Vaccine Trials Network.

J Clin Invest. 2019 Nov 1;129(11):4769-4785. doi: 10.1172/JCI128699.

7.

Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle.

Brouwer PJM, Antanasijevic A, Berndsen Z, Yasmeen A, Fiala B, Bijl TPL, Bontjer I, Bale JB, Sheffler W, Allen JD, Schorcht A, Burger JA, Camacho M, Ellis D, Cottrell CA, Behrens AJ, Catalano M, Del Moral-Sánchez I, Ketas TJ, LaBranche C, van Gils MJ, Sliepen K, Stewart LJ, Crispin M, Montefiori DC, Baker D, Moore JP, Klasse PJ, Ward AB, King NP, Sanders RW.

Nat Commun. 2019 Sep 19;10(1):4272. doi: 10.1038/s41467-019-12080-1.

8.

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.

Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, Swann EM, Bekker LG, Innes C, Lazarus E, Morris L, Mkhize NN, Ferrari G, Montefiori DC, Shen X, Sawant S, Yates N, Hural J, Isaacs A, Phogat S, DiazGranados CA, Lee C, Sinangil F, Michael NL, Robb ML, Kublin JG, Gilbert PB, McElrath MJ, Tomaras GD, Corey L.

Sci Transl Med. 2019 Sep 18;11(510). pii: eaax1880. doi: 10.1126/scitranslmed.aax1880.

PMID:
31534016
9.

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.

LaBranche CC, Henderson R, Hsu A, Behrens S, Chen X, Zhou T, Wiehe K, Saunders KO, Alam SM, Bonsignori M, Borgnia MJ, Sattentau QJ, Eaton A, Greene K, Gao H, Liao HX, Williams WB, Peacock J, Tang H, Perez LG, Edwards RJ, Kepler TB, Korber BT, Kwong PD, Mascola JR, Acharya P, Haynes BF, Montefiori DC.

PLoS Pathog. 2019 Sep 17;15(9):e1008026. doi: 10.1371/journal.ppat.1008026. eCollection 2019 Sep.

10.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B.

Cell Host Microbe. 2019 Aug 14;26(2):296. doi: 10.1016/j.chom.2019.07.016. No abstract available.

11.

Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes.

Gach JS, Mara KJV, LaBranche CC, van Gils MJ, McCoy LE, Klasse PJ, Montefiori DC, Sanders RW, Moore JP, Forthal DN.

J Virol. 2019 Sep 30;93(20). pii: e01188-19. doi: 10.1128/JVI.01188-19. Print 2019 Oct 15.

PMID:
31375582
12.

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.

Wee EG, Moyo NA, Saunders KO, LaBranche C, Donati F, Capucci S, Parks R, Borthwick N, Hannoun Z, Montefiori DC, Haynes BF, Hanke T.

Mol Ther Methods Clin Dev. 2019 Jun 29;14:148-160. doi: 10.1016/j.omtm.2019.06.003. eCollection 2019 Sep 13.

13.

Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.

Styles TM, Gangadhara S, Reddy PBJ, Hicks S, LaBranche CC, Montefiori DC, Derdeyn CA, Kozlowski PA, Velu V, Amara RR.

J Virol. 2019 Sep 30;93(20). pii: e00934-19. doi: 10.1128/JVI.00934-19. Print 2019 Oct 15.

PMID:
31341049
14.

Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations.

Han Q, Jones JA, Nicely NI, Reed RK, Shen X, Mansouri K, Louder M, Trama AM, Alam SM, Edwards RJ, Bonsignori M, Tomaras GD, Korber B, Montefiori DC, Mascola JR, Seaman MS, Haynes BF, Saunders KO.

Nat Commun. 2019 Jul 1;10(1):2898. doi: 10.1038/s41467-019-10899-2.

15.

Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques.

Escolano A, Gristick HB, Abernathy ME, Merkenschlager J, Gautam R, Oliveira TY, Pai J, West AP Jr, Barnes CO, Cohen AA, Wang H, Golijanin J, Yost D, Keeffe JR, Wang Z, Zhao P, Yao KH, Bauer J, Nogueira L, Gao H, Voll AV, Montefiori DC, Seaman MS, Gazumyan A, Silva M, McGuire AT, Stamatatos L, Irvine DJ, Wells L, Martin MA, Bjorkman PJ, Nussenzweig MC.

Nature. 2019 Jun;570(7762):468-473. doi: 10.1038/s41586-019-1250-z. Epub 2019 May 29.

PMID:
31142836
16.

Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence.

Sliepen K, Han BW, Bontjer I, Mooij P, Garces F, Behrens AJ, Rantalainen K, Kumar S, Sarkar A, Brouwer PJM, Hua Y, Tolazzi M, Schermer E, Torres JL, Ozorowski G, van der Woude P, de la Peña AT, van Breemen MJ, Camacho-Sánchez JM, Burger JA, Medina-Ramírez M, González N, Alcami J, LaBranche C, Scarlatti G, van Gils MJ, Crispin M, Montefiori DC, Ward AB, Koopman G, Moore JP, Shattock RJ, Bogers WM, Wilson IA, Sanders RW.

Nat Commun. 2019 May 29;10(1):2355. doi: 10.1038/s41467-019-10262-5.

17.

A Single Substitution in gp41 Modulates the Neutralization Profile of SHIV during In Vivo Adaptation.

Wang Q, Liu L, Ren W, Gettie A, Wang H, Liang Q, Shi X, Montefiori DC, Zhou T, Zhang L.

Cell Rep. 2019 May 28;27(9):2593-2607.e5. doi: 10.1016/j.celrep.2019.04.108.

18.

Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.

Jones DI, Pollara JJ, Johnson-Weaver BT, LaBranche CC, Montefiori DC, Pickup DJ, Permar SR, Abraham SN, Maddaloni M, Pascual DW, Staats HF.

J Virol. 2019 Jun 28;93(14). pii: e00475-19. doi: 10.1128/JVI.00475-19. Print 2019 Jul 15.

PMID:
31068425
19.

Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection.

Pittala S, Bagley K, Schwartz JA, Brown EP, Weiner JA, Prado IJ, Zhang W, Xu R, Ota-Setlik A, Pal R, Shen X, Beck C, Ferrari G, Lewis GK, LaBranche CC, Montefiori DC, Tomaras GD, Alter G, Roederer M, Fouts TR, Ackerman ME, Bailey-Kellogg C.

Mol Syst Biol. 2019 May 2;15(5):e8747. doi: 10.15252/msb.20188747.

20.

Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques.

Pardi N, LaBranche CC, Ferrari G, Cain DW, Tombácz I, Parks RJ, Muramatsu H, Mui BL, Tam YK, Karikó K, Polacino P, Barbosa CJ, Madden TD, Hope MJ, Haynes BF, Montefiori DC, Hu SL, Weissman D.

Mol Ther Nucleic Acids. 2019 Apr 15;15:36-47. doi: 10.1016/j.omtn.2019.03.003. Epub 2019 Mar 21.

21.

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.

LaBranche CC, McGuire AT, Gray MD, Behrens S, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC.

PLoS Pathog. 2019 Mar 26;15(3):e1007646. doi: 10.1371/journal.ppat.1007646. eCollection 2019 Mar.

22.

Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models.

Pollara J, Jones DI, Huffman T, Edwards RW, Dennis M, Li SH, Jha S, Goodman D, Kumar A, LaBranche CC, Montefiori DC, Fouda GG, Hope TJ, Tomaras GD, Staats HF, Ferrari G, Permar SR.

J Virol. 2019 May 1;93(10). pii: e02119-18. doi: 10.1128/JVI.02119-18. Print 2019 May 15.

23.

Oligomannose Glycopeptide Conjugates Elicit Antibodies Targeting the Glycan Core Rather than Its Extremities.

Nguyen DN, Xu B, Stanfield RL, Bailey JK, Horiya S, Temme JS, Leon DR, LaBranche CC, Montefiori DC, Costello CE, Wilson IA, Krauss IJ.

ACS Cent Sci. 2019 Feb 27;5(2):237-249. doi: 10.1021/acscentsci.8b00588. Epub 2019 Feb 6.

24.

Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques.

Rosenberg YJ, Lewis GK, Montefiori DC, LaBranche CC, Lewis MG, Urban LA, Lees JP, Mao L, Jiang X.

PLoS One. 2019 Feb 20;14(2):e0212649. doi: 10.1371/journal.pone.0212649. eCollection 2019.

25.

HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge.

Jones AT, Shen X, Walter KL, LaBranche CC, Wyatt LS, Tomaras GD, Montefiori DC, Moss B, Barouch DH, Clements JD, Kozlowski PA, Varadarajan R, Amara RR.

Nat Commun. 2019 Feb 18;10(1):798. doi: 10.1038/s41467-019-08739-4.

26.

Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.

Bresk CA, Hofer T, Wilmschen S, Krismer M, Beierfuß A, Effantin G, Weissenhorn W, Hogan MJ, Jordan APO, Gelman RS, Montefiori DC, Liao HX, Schmitz JE, Haynes BF, von Laer D, Kimpel J.

Viruses. 2019 Feb 15;11(2). pii: E159. doi: 10.3390/v11020159.

27.

Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1.

Tay MZ, Kunz EL, Deal A, Zhang L, Seaton KE, Rountree W, Eudailey JA, Heptinstall J, McRaven MD, Matias E, McGuire E, Yates NL, Perez LG, Montefiori DC, Overman RG, Hope TJ, Shen X, Kalilani L, Fouda GG, Tomaras GD, Permar SR.

J Virol. 2019 Mar 21;93(7). pii: e02084-18. doi: 10.1128/JVI.02084-18. Print 2019 Apr 1.

28.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B.

Cell Host Microbe. 2019 Jan 9;25(1):59-72.e8. doi: 10.1016/j.chom.2018.12.001. Erratum in: Cell Host Microbe. 2019 Aug 14;26(2):296.

29.

Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period.

Spearman P, Tomaras GD, Montefiori DC, Huang Y, Elizaga ML, Ferrari G, Alam SM, Isaacs A, Ahmed H, Hural J, McElrath MJ, Ouedraogo L, Pensiero M, Butler C, Kalams SA, Overton ET, Barnett SW; HVTN 088 Protocol Team and the NIH/NIAID HIV Vaccine Trials Network.

J Infect Dis. 2019 May 5;219(11):1755-1765. doi: 10.1093/infdis/jiz008.

PMID:
30615119
30.

Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.

Chukwuma VU, Kose N, Sather DN, Sapparapu G, Falk R, King H, Singh V, Lampley R, Malherbe DC, Ditto NT, Sullivan JT, Barnes T, Doranz BJ, Labranche CC, Montefiori DC, Kalams SA, Haigwood NL, Crowe JE Jr.

PLoS One. 2018 Dec 19;13(12):e0209437. doi: 10.1371/journal.pone.0209437. eCollection 2018.

31.

Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier.

Bonsignori M, Scott E, Wiehe K, Easterhoff D, Alam SM, Hwang KK, Cooper M, Xia SM, Zhang R, Montefiori DC, Henderson R, Nie X, Kelsoe G, Moody MA, Chen X, Joyce MG, Kwong PD, Connors M, Mascola JR, McGuire AT, Stamatatos L, Medina-Ramírez M, Sanders RW, Saunders KO, Kepler TB, Haynes BF.

Immunity. 2018 Dec 18;49(6):1162-1174.e8. doi: 10.1016/j.immuni.2018.10.015. Epub 2018 Dec 11.

32.

Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.

Ringe RP, Pugach P, Cottrell CA, LaBranche CC, Seabright GE, Ketas TJ, Ozorowski G, Kumar S, Schorcht A, van Gils MJ, Crispin M, Montefiori DC, Wilson IA, Ward AB, Sanders RW, Klasse PJ, Moore JP.

J Virol. 2019 Feb 5;93(4). pii: e01656-18. doi: 10.1128/JVI.01656-18. Print 2019 Feb 15.

33.

Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

Asbach B, Kibler KV, Köstler J, Perdiguero B, Yates NL, Stanfield-Oakley S, Tomaras GD, Kao SF, Foulds KE, Roederer M, Seaman MS, Montefiori DC, Parks R, Ferrari G, Forthal DN, Phogat S, Tartaglia J, Barnett SW, Self SG, Gottardo R, Cristillo AD, Weiss DE, Galmin L, Ding S, Heeney JL, Esteban M, Jacobs BL, Pantaleo G, Wagner R.

J Virol. 2019 Jan 17;93(3). pii: e01529-18. doi: 10.1128/JVI.01529-18. Print 2019 Feb 1.

34.

Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL.

J Virol. 2019 Jan 17;93(3). pii: e01513-18. doi: 10.1128/JVI.01513-18. Print 2019 Feb 1. Erratum in: J Virol. 2019 Oct 15;93(21):.

35.

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.

LaBranche CC, McGuire AT, Gray MD, Behrens S, Kwong PDK, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Chen X, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC.

PLoS Pathog. 2018 Nov 5;14(11):e1007431. doi: 10.1371/journal.ppat.1007431. eCollection 2018 Nov. Erratum in: PLoS Pathog. 2019 Mar 26;15(3):e1007646.

36.

Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N-Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition.

Cai H, Zhang RS, Orwenyo J, Giddens J, Yang Q, LaBranche CC, Montefiori DC, Wang LX.

J Med Chem. 2018 Nov 21;61(22):10116-10125. doi: 10.1021/acs.jmedchem.8b01290. Epub 2018 Nov 8.

PMID:
30384610
37.

IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells.

Blasi M, Negri D, LaBranche C, Alam SM, Baker EJ, Brunner EC, Gladden MA, Michelini Z, Vandergrift NA, Wiehe KJ, Parks R, Shen X, Bonsignori M, Tomaras GD, Ferrari G, Montefiori DC, Santra S, Haynes BF, Moody MA, Cara A, Klotman ME.

Commun Biol. 2018 Sep 5;1:134. doi: 10.1038/s42003-018-0131-6. eCollection 2018.

38.

Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles.

Purwar M, Pokorski JK, Singh P, Bhattacharyya S, Arendt H, DeStefano J, La Branche CC, Montefiori DC, Finn MG, Varadarajan R.

Vaccine. 2018 Oct 8;36(42):6345-6353. doi: 10.1016/j.vaccine.2018.07.032. Epub 2018 Sep 14.

39.

Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys.

Himes JE, Goswami R, Mangan RJ, Kumar A, Jeffries TL Jr, Eudailey JA, Heimsath H, Nguyen QN, Pollara J, LaBranche C, Chen M, Vandergrift NA, Peacock JW, Schiro F, Midkiff C, Ferrari G, Montefiori DC, Hernandez XA, Aye PP, Permar SR.

Mucosal Immunol. 2018 Nov;11(6):1716-1726. doi: 10.1038/s41385-018-0067-7. Epub 2018 Aug 16.

40.

Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.

Rathore U, Purwar M, Vignesh VS, Das R, Kumar AA, Bhattacharyya S, Arendt H, DeStefano J, Wilson A, Parks C, La Branche CC, Montefiori DC, Varadarajan R.

J Biol Chem. 2018 Sep 28;293(39):15002-15020. doi: 10.1074/jbc.RA118.005006. Epub 2018 Aug 9.

41.

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H.

Lancet. 2018 Jul 21;392(10143):232-243. doi: 10.1016/S0140-6736(18)31364-3. Epub 2018 Jul 6.

42.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ; HVTN 100 Protocol Team.

Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.

43.

Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus.

Manoharan VK, Khattar SK, LaBranche CC, Montefiori DC, Samal SK.

Sci Rep. 2018 Jun 12;8(1):8952. doi: 10.1038/s41598-018-27433-x.

44.

Multivalent Antigen Presentation Enhances the Immunogenicity of a Synthetic Three-Component HIV-1 V3 Glycopeptide Vaccine.

Cai H, Zhang R, Orwenyo J, Giddens J, Yang Q, LaBranche CC, Montefiori DC, Wang LX.

ACS Cent Sci. 2018 May 23;4(5):582-589. doi: 10.1021/acscentsci.8b00060. Epub 2018 May 7.

45.

Control of Heterologous Simian Immunodeficiency Virus SIVsmE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques.

Singh S, Ramírez-Salazar EG, Doueiri R, Valentin A, Rosati M, Hu X, Keele BF, Shen X, Tomaras GD, Ferrari G, LaBranche C, Montefiori DC, Das J, Alter G, Trinh HV, Hamlin C, Rao M, Dayton F, Bear J, Chowdhury B, Alicea C, Lifson JD, Broderick KE, Sardesai NY, Sivananthan SJ, Fox CB, Reed SG, Venzon DJ, Hirsch VM, Pavlakis GN, Felber BK.

J Virol. 2018 Jul 17;92(15). pii: e00281-18. doi: 10.1128/JVI.00281-18. Print 2018 Aug 1.

46.

HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition.

Vaccari M, Fourati S, Gordon SN, Brown DR, Bissa M, Schifanella L, Silva de Castro I, Doster MN, Galli V, Omsland M, Fujikawa D, Gorini G, Liyanage NPM, Trinh HV, McKinnon KM, Foulds KE, Keele BF, Roederer M, Koup RA, Shen X, Tomaras GD, Wong MP, Munoz KJ, Gach JS, Forthal DN, Montefiori DC, Venzon DJ, Felber BK, Rosati M, Pavlakis GN, Rao M, Sekaly RP, Franchini G.

Nat Med. 2018 Jun;24(6):847-856. doi: 10.1038/s41591-018-0025-7. Epub 2018 May 21.

47.

Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection.

Song H, Giorgi EE, Ganusov VV, Cai F, Athreya G, Yoon H, Carja O, Hora B, Hraber P, Romero-Severson E, Jiang C, Li X, Wang S, Li H, Salazar-Gonzalez JF, Salazar MG, Goonetilleke N, Keele BF, Montefiori DC, Cohen MS, Shaw GM, Hahn BH, McMichael AJ, Haynes BF, Korber B, Bhattacharya T, Gao F.

Nat Commun. 2018 May 15;9(1):1928. doi: 10.1038/s41467-018-04217-5.

48.

Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism.

Scinto HB, Gupta S, Thorat S, Mukhtar MM, Griffiths A, Delgado J, Plake E, Vyas HK, Strickland A, Byrareddy SN, Montefiori DC, LaBranche C, Pal R, Treece J, Orndorff S, Ferrari MG, Weiss D, Chenine AL, McLinden R, Michael N, Kim JH, Robb ML, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Ruprecht RM.

J Virol. 2018 Jun 29;92(14). pii: e02222-17. doi: 10.1128/JVI.02222-17. Print 2018 Jul 15.

49.

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses.

Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, Moody MA, Verkerke HP, Myles A, Willis E, LaBranche CC, Montefiori DC, Lobby JL, Saunders KO, Liao HX, Korber BT, Sutherland LL, Scearce RM, Hraber PT, Tombácz I, Muramatsu H, Ni H, Balikov DA, Li C, Mui BL, Tam YK, Krammer F, Karikó K, Polacino P, Eisenlohr LC, Madden TD, Hope MJ, Lewis MG, Lee KK, Hu SL, Hensley SE, Cancro MP, Haynes BF, Weissman D.

J Exp Med. 2018 Jun 4;215(6):1571-1588. doi: 10.1084/jem.20171450. Epub 2018 May 8.

50.

Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.

Wen Y, Trinh HV, Linton CE, Tani C, Norais N, Martinez-Guzman D, Ramesh P, Sun Y, Situ F, Karaca-Griffin S, Hamlin C, Onkar S, Tian S, Hilt S, Malyala P, Lodaya R, Li N, Otten G, Palladino G, Friedrich K, Aggarwal Y, LaBranche C, Duffy R, Shen X, Tomaras GD, Montefiori DC, Fulp W, Gottardo R, Burke B, Ulmer JB, Zolla-Pazner S, Liao HX, Haynes BF, Michael NL, Kim JH, Rao M, O'Connell RJ, Carfi A, Barnett SW.

PLoS One. 2018 Apr 26;13(4):e0194266. doi: 10.1371/journal.pone.0194266. eCollection 2018.

Supplemental Content

Loading ...
Support Center